AstraZeneca Says Lynparza Combination Delays Progression Risk in Prostate Cancer
15 Februar 2022 - 8:39AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Tuesday that a Phase 3 trial of Lynparza
plus abiraterone showed that the drug combination reduced risk of
disease progression in patients with prostate cancer.
The Anglo-Swedish pharma giant said Lynparza plus abiraterone
reduced risk of disease progression by 34% compared with the
standard of care.
Prostate cancer is the second most common cancer in male
patients, causing around 375,000 deaths in 2020, AstraZeneca
said.
Results also showed a favorable trend toward improved overall
survival, the company said.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
February 15, 2022 02:24 ET (07:24 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
